ADVERTISEMENT
  • News
  • New York
  • Technology
  • Culture
  • Entertainment
  • Sport
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Tuesday, June 24, 2025
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Business Pharmacy

U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey

The FINANCIAL by The FINANCIAL
March 2, 2016
in Pharmacy
Reading Time: 3 mins read
8
A A
0
Share on FacebookShare on Twitter

The FINANCIAL — Gilead Sciences, Inc. on March 1 announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.

Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single tablet regimen for the treatment of HIV.

Odefsey is indicated as a complete regimen for the treatment of HIV-1 infection in patients 12 years of age and older who have no antiretroviral treatment history and HIV-1 RNA levels less than or equal to 100,000 copies per mL. Odefsey is also indicated as replacement for a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey. No dosage adjustment of Odefsey is required in patients with estimated creatinine clearance greater than or equal to 30 mL per minute, according to Gilead.

RelatedPosts

A Closer Look at Bioactive Peptides and Their Impact on Health

Roche ranked the most sustainable healthcare company in the DJSI

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Odefsey has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis, and post treatment acute exacerbation of hepatitis B. See below for important safety information.

TAF is a novel targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread (tenofovir disoproxil fumarate, TDF). TAF has also demonstrated improvement in surrogate laboratory markers of renal and bone safety as compared to TDF in clinical trials in combination with other antiretroviral agents. Data show that because TAF enters cells, including HIV-infected cells, more efficiently than TDF, it can be given at a much lower dose and there is 90 percent less tenofovir in the bloodstream.

“As people are living longer with HIV, there is an increasing need to develop new treatments that are tolerable and help address long-term health for patients,” said John C. Martin, PhD, Chairman and Chief Executive Officer, Gilead Sciences. “Odefsey’s safety, efficacy and tolerability profile offers a new treatment option to support the needs of a range of patients and represents Gilead’s commitment to innovation in the field of HIV.”

The approval is supported by a bioequivalence study demonstrating that Odefsey achieved similar drug levels of emtricitabine and TAF in the blood as Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) and similar drug levels of rilpivirine as Edurant (rilpivirine 25 mg). The safety, efficacy and tolerability of Odefsey is supported by clinical studies of rilpivirine-based therapy (administered as R+F/TDF or R/F/TDF) and F/TAF-based therapy (administered as E/C/F/TAF) in a range of patients with HIV, including treatment-naïve adults and adolescents, virologically suppressed adults who switched from PI-, NNRTI- and INSTI-based regimens and virologically suppressed adults with mild-to-moderate renal impairment.

The Odefsey approval is part of an ongoing development and commercialization agreement between Gilead and Janssen, first established in 2009. Under this agreement, Gilead is responsible for the manufacturing, registration, distribution and commercialization of the product in most countries, while Janssen will distribute it in approximately 17 markets and have co-detailing rights in several key markets, including the United States. The original agreement was established for the development and commercialization of Complera®, marketed as Eviplera® in the European Union, and expanded in 2014 to include Odefsey.

Odefsey does not cure HIV infection or AIDS.

Patient Assistance Programs

Gilead’s U.S. Advancing Access program provides assistance to appropriate patients in the United States who are uninsured, underinsured or who need financial assistance to pay for their medications, including Odefsey.

The program offers information and assistance for patients, including:

Access to agents who can provide information related to coverage and insurance-related questions.

The Advancing Access Copay Coupon Program, which provides co-pay assistance for eligible patients with private insurance who need assistance paying for out-of-pocket medication costs.

The Advancing Access Patient Assistance Program and Truvada® Medication Assistance Program, which will provide Gilead medications at no charge for eligible patients with no other insurance options.

Additionally, Gilead is working closely with the ADAP Crisis Task Force, as the company has done for each of its other HIV medications, to provide discounts to state AIDS Drug Assistance Programs (ADAPs) that will help ensure access to Odefsey for patients who receive medications through these programs.

 

Related Posts

A Closer Look at Bioactive Peptides and Their Impact on Health
Clinics

A Closer Look at Bioactive Peptides and Their Impact on Health

by Accessily
October 15, 2024
0

Introduction to Bioactive Peptides What are Bioactive Peptides? Bioactive peptides are short protein fragments, typically ranging from 2 to 20...

Read more
Roche ranked the most sustainable healthcare company in the DJSI

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020
Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

November 16, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 12, 2020

Discussion about this post

  • Trending
  • Comments
  • Latest
Teaching porn literacy

A sizable percentage of internet porn users, roughly 40% are women

January 17, 2024
EasyJet to fly to London from Stockholm Arlanda

The London Diplomatic List, Addresses, Contacts & Working Hours

January 23, 2023
Ampersand wins £22m five-year contract at London Zoo

Ampersand wins £22m five-year contract at London Zoo

June 25, 2012
Matthew H. Fleeger Drives Strategic Growth at Gulf Coast Western Through Technology Integration

Matthew H. Fleeger Drives Strategic Growth at Gulf Coast Western Through Technology Integration

June 19, 2025
Teaching porn literacy

Teaching porn literacy

January 17, 2024
Charged With Retail Theft? What to Know Before Court

Charged With Retail Theft? What to Know Before Court

June 24, 2025
Jewish General Hospital, Montreal is the first hospitals in the world to fully implement EIAS across all surgical disciplines

Jewish General Hospital, Montreal is the first hospitals in the world to fully implement EIAS across all surgical disciplines

June 24, 2025
Survey: Majority of CFOs prioritizing ESG investment

The CFO’s Five Hidden Cyber-Cost Centers (and How to Shrink Them)

June 24, 2025
President of Ukraine. Stop Russia

Ukrainian President to make first visit to Council of Europe in Strasbourg amid escalating war in Ukraine

June 23, 2025
Energy Management in Facilities: Tools for Calculating Efficiency

Energy Management in Facilities: Tools for Calculating Efficiency

June 23, 2025
ADVERTISEMENT

Popular Last 24h

  • Teaching porn literacy

    A sizable percentage of internet porn users, roughly 40% are women

    332 shares
    Share 133 Tweet 83
  • Ampersand wins £22m five-year contract at London Zoo

    3724 shares
    Share 1490 Tweet 931
  • Osman Gunes Cizmeci on Apple’s Liquid Glass: Beautiful, But at What Cost?

    25 shares
    Share 10 Tweet 6
  • Leon Botstein’s Five-Decade Transformation at Bard College

    357 shares
    Share 143 Tweet 89
  • Levi Pettit Launches Dornick Wealth Management With a Personalized Approach to Client Relationships

    21 shares
    Share 8 Tweet 5
  • Teaching porn literacy

    163 shares
    Share 65 Tweet 41
  • Ukrainian President to make first visit to Council of Europe in Strasbourg amid escalating war in Ukraine

    19 shares
    Share 8 Tweet 5

LATEST POSTS

Charged With Retail Theft? What to Know Before Court

Charged With Retail Theft? What to Know Before Court

June 24, 2025
Jewish General Hospital, Montreal is the first hospitals in the world to fully implement EIAS across all surgical disciplines

Jewish General Hospital, Montreal is the first hospitals in the world to fully implement EIAS across all surgical disciplines

June 24, 2025
Survey: Majority of CFOs prioritizing ESG investment

The CFO’s Five Hidden Cyber-Cost Centers (and How to Shrink Them)

June 24, 2025
President of Ukraine. Stop Russia

Ukrainian President to make first visit to Council of Europe in Strasbourg amid escalating war in Ukraine

June 23, 2025
Energy Management in Facilities: Tools for Calculating Efficiency

Energy Management in Facilities: Tools for Calculating Efficiency

June 23, 2025
Levi Pettit Launches Dornick Wealth Management With a Personalized Approach to Client Relationships

Levi Pettit Launches Dornick Wealth Management With a Personalized Approach to Client Relationships

June 23, 2025
Osman Gunes Cizmeci on Apple’s Liquid Glass: Beautiful, But at What Cost?

Osman Gunes Cizmeci on Apple’s Liquid Glass: Beautiful, But at What Cost?

June 23, 2025
In the U.S. and abroad, more young adults are living with their parents

Why More Adults Are Reconsidering Old Habits in 2025

June 23, 2025
CityBlue Hotels opens its first Beach Property in Kenya

CityBlue Hotels opens its first Beach Property in Kenya

June 19, 2025
65% of Europeans see EU membership as a good thing, the highest result since 2007 

The Enchantment of Ukrainian Women and Building Bridges through Luludate

June 19, 2025

LATESTBUSINESS

Valor Hospitality Partners announces two significant deals in West Africa,

Valor Hospitality Partners announces two significant deals in West Africa,

by The FINANCIAL
June 19, 2025
0

Markets will drop quickly if US enters Israel-Iran conflict: deVere CEO

Markets will drop quickly if US enters Israel-Iran conflict: deVere CEO

by The FINANCIAL
June 19, 2025
0

Matthew H. Fleeger Drives Strategic Growth at Gulf Coast Western Through Technology Integration

Matthew H. Fleeger Drives Strategic Growth at Gulf Coast Western Through Technology Integration

by The FINANCIAL
June 19, 2025
0

Iconiq 777 Hosts Pathways to Apprenticeship Awards Ceremony in Newark

Iconiq 777 Hosts Pathways to Apprenticeship Awards Ceremony in Newark

by The FINANCIAL
June 17, 2025
0

Tips for Remodeling on a Budget

Tips for Remodeling on a Budget

by The FINANCIAL
June 17, 2025
0

 ‘Why Did My Car Insurance Go Up for No Reason?’

Insurers boost private assets allocations as capital increases

by The FINANCIAL
June 17, 2025
0

Elite Lauches in Lebanon

U.S. Counts 1,873 Listed Billion-Dollar Companies, More Than the Next Eight Economies Combined

by The FINANCIAL
June 17, 2025
0

7 Digital Marketing Techniques for Business Owners in 2020

Lockton Surprasses $4 Billion in FY2025 revenue

by The FINANCIAL
June 16, 2025
0

GET IN TOUCH

Submit guest post/Letters to the Editor:

editor (at) finchannel.com

Sales & Marketing: (+995 558) 03 03 03 Email: marketing (at) finchannel.com

Whatsup: (+995 599) 96 52 52

Georgia:

(+995 599) 96 52 52 Email: editor (@) finchannel.com

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2025 Intelligence Group llc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.